Drug Database
IV

ivosidenib

✓ Approved

Agios Pharmaceuticals, Inc. · 辅助诊断 · 辅助诊断

什么是 ivosidenib?

ivosidenib 是一种辅助诊断,由Agios Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

公司Agios Pharmaceuticals, Inc.
药物类别辅助诊断
给药途径Others
状态Approved

治疗适应症

ivosidenib 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedNeuro-oncology practice2026-11-18

Efficacy of vorasidenib for patients with IDH-mutant glioma previously treated with ivosidenib.

Schultz Sydney E SE, Barreto Jason N JN, Mead-Harvey Carolyn C, Caron Samantha J SJ et al.

Isocitrate dehydrogenase-1 (IDH-1) inhibitor ivosidenib and dual-IDH1/2 inhibitor vorasidenib have demonstrated clinical activity in the treatment of IDH-mutant gliomas. We evaluated the efficacy of vorasidenib in patients with prior exposure to ivosidenib. Retrospective review of patients with IDH-mutant glioma treated with vorasidenib who had prior treatment with ivosidenib. Previous treatments, radiographic response, and adverse events were collected and analyzed descriptively. Twenty-nine patients (median age 42, 34% female) were evaluated. Tumor types included IDH-mutant astrocytoma (grade 2 n = 9, 31%; grade 3 n = 3, 10%; grade 4 n = 3, 10%) and oligodendroglioma (grade 2 n = 10, 34%; grade 3 n = 4, 14%). Treatments received prior to ivosidenib included surgical resection (n = 23, 79%), radiation (n = 16, 55%), temozolomide (n = 15, 52%), procarbazine, lomustine, vincristine (PCV, n = 2, 7%), bevacizumab (n = 3, 10%), lomustine (n = 2, 7%), and pembrolizumab (n = 1, 3%). Four patients received additional treatment in between ivosidenib and vorasidenib treatment.Ten of 16 (63%) patients who experienced disease progression on ivosidenib achieved stable disease and remain on vorasidenib, while 6 (37%) had continued progression. Eleven patients with stable disease on ivosidenib transitioned to vorasidenib following FDA approval and remained without progression. Two patients who transitioned to vorasidenib due to ivosidenib-related adverse effects (diarrhea and fatigue) experienced symptom resolution and maintained disease stability. Vorasidenib demonstrated clinical efficacy in patients with IDH-mutant gliomas previously treated with ivosidenib. Notably, stable patients who transitioned maintained disease stability, while some of those with progressive disease achieved stabilization with vorasidenib. These findings support vorasidenib as a viable therapeutic option following ivosidenib exposure.

PMID 43047530
阅读全文 →
PubMedMediterranean journal of hematology and infectious diseases2026-11-18

Optimization of the Clinical Journey of Unfit Patients with Newly Diagnosed IDH1m Acute Myeloid Leukemia.

Venditti Adriano A, Borlenghi Erika E, Candoni Anna A, Curti Antonio A et al.

The management of acute myeloid leukemia (AML) in elderly or unfit patients has undergone a paradigm shift with the integration of molecular diagnostics and targeted therapies. Among actionable alterations, IDH1 mutations define a biologically distinct subgroup, for which ivosidenib combined with azacitidine has recently emerged as standard of care. However, initial clinical management remains complex. Three main themes emerged from the expert panel's discussion: all patients should be tested for IDH1m, with a turnaround time of 3-5 days; adequate patient monitoring during treatment is essential to detect the earliest signs of differentiation syndrome and QTc prolongation; appropriate management of concomitant therapies is required, not only for azole derivatives administered for antifungal prophylaxis, where needed. This paper provides a comprehensive, evidence-based framework to optimize early management in unfit patients with newly diagnosed IDH1-mutated AML, integrating data from randomized trials, real-world studies, and updated evidence on antifungal prophylaxis and drug-drug interactions in the era of targeted therapies.

PMID 43048629
阅读全文 →
PubMedJournal for nurses in professional development2026-11-18

From Diagnostic Error to Diagnostic Excellence: Building Diagnostic Competence Across the Health Care Team.

Griffith Patricia B PB, Park Chan W CW

When a diagnosis no longer fits the clinical picture, nurses often recognize the discrepancy first. This first column in a yearlong series explores diagnostic excellence as a shared team responsibility and highlights nurses' contributions to observation, information integration, communication, and advocacy throughout the diagnostic process. Drawing on current diagnostic safety initiatives, the article outlines opportunities for nursing professional development practitioners to strengthen diagnostic reasoning and team-based competencies that enhance patient safety and care quality.

PMID 43046290
阅读全文 →
PubMedVeterinary and comparative oncology2026-11-18

Diagnostic and Translational Challenges in Canine Endocrine and Neuroendocrine Neoplasms: A Comparative Pathology Perspective.

Mitze Stefanie S, Williams Jonathan J, Davison Lucy Jane LJ, Xia Dong D et al.

The recognition and detection of endocrine and neuroendocrine neoplasms (NENs) in dogs and humans is challenging. This is, in part, because some are non-functional, and where hormone hypersecretion occurs, it can lead to a great variety of clinical syndromes. Additionally, metastatic patterns vary according to the primary anatomical site, and the typically slow growth of many endocrine tumours/NENs may lead to underestimation of biological aggressiveness and misclassification as benign disease. In human medicine, diagnostic evaluation relies on a comprehensive, anatomical site-specific histopathologic framework, incorporating immunohistochemistry as formalised in the 2025 World Health Organisation classification of endocrine tumours/NENs. In contrast, veterinary diagnostic frameworks for canine endocrine tumours/NENs remain comparatively underdeveloped, with limited standardisation of terminology, grading systems, and validated cut-off values. This review aims to raise awareness of key diagnostic challenges associated with the most clinically prevalent canine endocrine tumours/NENs: insulinoma, phaeochromocytoma and cortisol-producing adrenocortical tumours. Emphasis is placed on histopathological characterisation using immunohistochemistry, drawing parallels with established human diagnostic algorithms where appropriate. By synthesising current knowledge from human and canine pathology, this review highlights critical gaps in veterinary diagnostic practice and identifies opportunities for harmonisation of classification strategies. The development of standardised diagnostic guidelines has the potential not only to improve clinical management of affected dogs but also to strengthen the translational value of spontaneous canine endocrine tumours/NENs within the field of comparative oncology and One Medicine.

PMID 43046768
阅读全文 →
PubMedNeuro-oncology practice2026-11-18

Machine learning models for predicting pseudoprogression in glioblastoma: A systematic review and diagnostic meta-analysis.

Kotochinsky Martin M, Silva Yasmin Picanco YP, Goyal Abhishek A, Łajczak Paweł P et al.

Artificial intelligence and machine learning (ML) are increasingly being used in medical practice, particularly in neuroradiology. Glioblastoma, a highly aggressive brain tumor, poses significant diagnostic challenges, especially in differentiating actual tumor progression (TP) from pseudoprogression (PsP) using conventional magnetic resonance imaging (MRI). Machine learning and AI techniques offer a promising approach, but their diagnostic accuracy remains debated. A systematic review and diagnostic meta-analysis were performed to assess the diagnostic efficacy of ML algorithms applied in MRI of glioblastoma patients to differentiate between TP and PsP. We evaluated classical ML and deep learning models using diffusion-weighted, perfusion-weighted, and structural MRI inputs to differentiate PsP from true progression in glioblastoma. PubMed, Scopus, and Cochrane databases were searched. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), accuracy, and area under the curve (AUC) were calculated using a random-effects model. Eleven studies involving a total of 676 patients were included. Machine learning models demonstrated a pooled sensitivity of 0.899 (95% CI, 0.843-0.936; I² = 16.3%) and a specificity of 0.766 (95% CI, 0.647-0.854; I² = 38.8%). The DOR was 27.059 (95% CI, 11.094-65.999; I² = 61.9%), and the overall accuracy was 0.85 (95% CI, 0.788-0.897; I² = 66%). The AUC was estimated at 0.88 (95% CI, 0.727-0.896). Deek's funnel plot showed no significant publication bias (P = .283). Machine learning-based models demonstrate high diagnostic accuracy in distinguishing TP from PsP in glioblastoma patients, offering a promising tool to enhance radiological assessment and support clinical decision-making. However, further standardization across algorithms and datasets is needed to facilitate their integration into routine clinical practice.

PMID 43047455
阅读全文 →
PubMedBMC oral health2026-11-18

Occlusion Chatterbox: an origami-inspired robotic device for enhancing dental occlusion training.

Motamedosanaye Vahideh V, Nikdelan Saeed S, Malekpour Parnia P, Safai Saeed S et al.

Occlusal morphology is a fundamental component of dental education and is essential for restorative, prosthodontic, and orthodontic procedures. However, traditional teaching methods-such as wax carving, plastic tooth models, and two-dimensional illustrations-often fail to provide learners with an interactive and spatially accurate understanding of occlusal features. We introduce the Occlusion Chatterbox, a novel origami-inspired robotic educational device designed to support the teaching and learning of dental occlusion. The device transforms the geometry of a traditional paper fortune teller (chatterbox) into a foldable structure representing occlusal surfaces. Each modular flap corresponds to a cusp or ridge and is actuated by stepper motors controlled via an ESP32-WROOM microcontroller. A programable LED system provides real-time color-coded guidance of the occlusal elements, synchronized with a companion Arduino-based software platform. A pilot study involving 23 third-year dental students compared the Occlusion Chatterbox with conventional instruction. Students trained with the device achieved significantly higher scientific assessment scores (7.45 ± 0.93 vs. 5.17 ± 1.99; p = 0.002) and reported greater satisfaction (43.18 ± 4.42 vs. 33.08 ± 6.02; p = 0.001), suggesting improved learning outcomes and student engagement. By combining tactile interaction, robotic articulation, and LED feedback, the Occlusion Chatterbox bridges the gap between the abstract concepts of occlusal morphology and concrete learner comprehension. It represents a low-cost, portable, and interactive alternative to static models and expensive virtual reality simulators, with the potential for broad adoption in preclinical dental curricula. To the best of our knowledge, this is the first reported origami-inspired robotic simulator specifically designed for teaching dental occlusion.

PMID 43046201
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多ivosidenib